|
1
|
Rathmann W and Giani G: Global prevalence
of diabetes: estimates for the year 2000 and projections for 2030.
Diabetes Care. 27:2568–2569; author reply 2569. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Olokoba AB, Obateru OA and Olokoba LB:
Type 2 diabetes mellitus: a review of current trends. Oman Med J.
27:269–273. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Saltiel AR: New perspectives into the
molecular pathogenesis and treatment of type 2 diabetes. Cell.
104:517–529. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bajaj M and Defronzo RA: Metabolic and
molecular basis of insulin resistance. J Nucl Cardiol. 10:311–323.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pendergrass M, Bertoldo A, Bonadonna R,
Nucci G, Mandarino L, Cobelli C and Defronzo RA: Muscle glucose
transport and phosphorylation in type 2 diabetic, obese
nondiabetic, and genetically predisposed individuals. Am J Physiol
Endocrinol Metab. 292:E92–E100. 2007. View Article : Google Scholar
|
|
6
|
Cusi K, Maezono K, Osman A, Pendergrass M,
Patti ME, Pratipanawatr T, DeFronzo RA, Kahn CR and Mandarino LJ:
Insulin resistance differentially affects the PI 3-kinase- and MAP
kinase-mediated signaling in human muscle. J Clin Invest.
105:311–320. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wilcox G: Insulin and insulin resistance.
Clin Biochem Rev. 26:19–39. 2005.PubMed/NCBI
|
|
8
|
Michalik L, Auwerx J, Berger JP,
Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T,
Lazar MA, O'Rahilly S, et al: International Union of Pharmacology.
LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev.
58:726–741. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee CH, Olson P and Evans RM: Minireview:
lipid metabolism, metabolic diseases, and peroxisome
proliferator-activated receptors. Endocrinology. 144:2201–2207.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vidal-Puig AJ, Considine RV, Jimenez-Liñan
M, Werman A, Pories WJ, Caro JF and Flier JS: Peroxisome
proliferator-activated receptor gene expression in human tissues.
Effects of obesity, weight loss, and regulation by insulin and
glucocorticoids. J Clin Invest. 99:2416–2422. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dubois M, Pattou F, Kerr-Conte J, Gmyr V,
Vandewalle B, Desreumaux P, Auwerx J, Schoonjans K and Lefebvre J:
Expression of peroxisome proliferator-activated receptor gamma
(PPARgamma) in normal human pancreatic islet cells. Diabetologia.
43:1165–1169. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bünger M, Hooiveld GJ, Kersten S and
Müller M: Exploration of PPAR functions by microarray technology -
a paradigm for nutrigenomics. Biochim Biophys Acta. 1771:1046–1064.
2007. View Article : Google Scholar
|
|
13
|
Superko HR: A review of combined
hyperlipidaemia and its treatment with fenofibrate. J Int Med Res.
17:99–112. 1989.PubMed/NCBI
|
|
14
|
Bajaj M, Suraamornkul S, Hardies LJ, Glass
L, Musi N and DeFronzo RA: Effects of peroxisome
proliferator-activated receptor (PPAR)-alpha and PPAR-gamma
agonists on glucose and lipid metabolism in patients with type 2
diabetes mellitus. Diabetologia. 50:1723–1731. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pickavance LC, Brand CL, Wassermann K and
Wilding JP: The dual PPARalpha/gamma agonist, ragaglitazar,
improves insulin sensitivity and metabolic profile equally with
pioglitazone in diabetic and dietary obese ZDF rats. Br J
Pharmacol. 144:308–316. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Reifel-Miller A, Otto K, Hawkins E, Barr
R, Bensch WR, Bull C, Dana S, Klausing K, Martin JA,
Rafaeloff-Phail R, et al: A peroxisome proliferator-activated
receptor alpha/gamma dual agonist with a unique in vitro profile
and potent glucose and lipid effects in rodent models of type 2
diabetes and dyslipidemia. Mol Endocrinol. 19:1593–1605. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Harrity T, Farrelly D, Tieman A, Chu C,
Kunselman L, Gu L, Ponticiello R, Cap M, Qu F, Shao C, et al:
Muraglitazar, a novel dual (alpha/gamma) peroxisome
proliferator-activated receptor activator, improves diabetes and
other metabolic abnormalities and preserves beta-cell function in
db/db mice. Diabetes. 55:240–248. 2006. View Article : Google Scholar
|
|
18
|
Mittra S, Sangle G, Tandon R, Sharma S,
Roy S, Khanna V, Gupta A, Sattigeri J, Sharma L, Priyadarsiny P, et
al: Increase in weight induced by muraglitazar, a dual
PPARalpha-gamma agonist, in db/db mice: adipogenesis/or oedema? Br
J Pharmacol. 150:480–487. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Adeghate E, Adem A, Hasan MY, Tekes K and
Kalasz H: Medicinal Chemistry and Actions of Dual and Pan PPAR
Modulators. Open Med Chem J. 5(Suppl 2): 93–98. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dat NT, Lee JH, Lee K, Hong YS, Kim YH and
Lee JJ: Phenolic constituents of Amorpha fruticosa that inhibit
NF-kappaB activation and related gene expression. J Nat Prod.
71:1696–1700. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cho JY, Kim PS, Park J, Yoo ES, Baik KU,
Kim YK and Park MH: Inhibitor of tumor necrosis factor-alpha
production in lipopolysaccharide-stimulated RAW264.7 cells from
Amorpha fruticosa. J Ethnopharmacol. 70:127–133. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee W, Ham J, Kwon HC, Kim YK and Kim SN:
Anti-diabetic effect of amorphastilbol through PPARα/γ dual
activation in db/db mice. Biochem Biophys Res Commun. 432:73–79.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee W, Ham J, Kwon HC, Yoon G, Bae GU, Kim
YK and Kim SN: Amorphastilbol exerts beneficial effects on glucose
and lipid metabolism in mice consuming a high-fat-diet. Int J Mol
Med. 36:527–533. 2015.PubMed/NCBI
|
|
24
|
Kim T, Lee W, Jeong KH, Song JH, Park SH,
Choi P, Kim SN, Lee S and Ham J: Total synthesis and dual PPARα/γ
agonist effects of amorphastilbol and its synthetic derivatives.
Bioorg Med Chem Lett. 22:4122–4126. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Soukas A, Socci ND, Saatkamp BD, Novelli S
and Friedman JM: Distinct transcriptional profiles of adipogenesis
in vivo and in vitro. J Biol Chem. 276:34167–34174. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zierath JR, He L, Gumà A, Odegoard
Wahlström E, Klip A and Wallberg-Henriksson H: Insulin action on
glucose transport and plasma membrane GLUT4 content in skeletal
muscle from patients with NIDDM. Diabetologia. 39:1180–1189. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nissen SE and Wolski K: Effect of
rosiglitazone on the risk of myocardial infarction and death from
cardiovascular causes. N Engl J Med. 356:2457–2471. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
U.S. Food and Drug Administration:
Rosiglitazone-containing diabetes medicines: Drug Safety
Communication - Removal of some prescribing and dispensing
restrictions. FDA Drug Safety Communication. 2013.
|
|
29
|
Lincoff AM, Wolski K, Nicholls SJ and
Nissen SE: Pioglitazone and risk of cardiovascular events in
patients with type 2 diabetes mellitus: a meta-analysis of
randomized trials. JAMA. 298:1180–1188. 2007. View Article : Google Scholar : PubMed/NCBI
|
